Global Influenza Market report published by Accurize Market Research forecast that the global market is expected to reach $7 billion by 2024; growing at a CAGR of 3.4% from 2017 to 2025. By geography, the Asia Pacific and North America are expected to grow at a CAGR of XX% and XX%, respectively, during the forecast period.
Request Sample: https://www.accurizemarketresearch.com/report/influenza-market/sample-request
Increasing study and development activities, technological improvements in recombinant DNA technology, and growing healthcare expenditure fuel the market
Increasing study and development activities, growing investment by companies for the improvement of influenza vaccine, technological improvements in recombinant DNA technology, the huge number of population with no immunization against influenza viruses in emerging markets, growing healthcare expenditure fuel the demand for the global influenza market. Furthermore, increasing healthcare expenditures, the aging population and increasing the occurrence of chronic diseases also boost the growth of the market.
The global influenza market has been bifurcated on the basis of vaccine, end-user, and geography. The vaccine segment is further segmented into trivalent and quadrivalent. The end-user segment includes children and adolescents, adults and the elderly. By geography, the market is segmented into North America, Europe, Asia-Pacific, and Rest of the World (RoW).
Request Customization: https://www.accurizemarketresearch.com/report/influenza-market/ask-for-customization
Top players in the market
The key players operational in the market includes Alvogen, Abbott Laboratories, Chiron Corporation, Daiichi Sankyo Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Nanotherapeutics Inc., Roche Holding Ag, Shionogi & Co. Ltd., Sinovac Biotech Ltd., AstraZeneca, Biocryst Pharmaceuticals Inc., CSL Limited, Emergent Biosolutions, GlaxoSmithKline, Protein Sciences Corporation, Sanofi Pasteur Inc. and Serum Institute Of India Pvt. Ltd.among others.